Madrigal Pharmaceuticals, Inc. (MDGL)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: United States
Exchange: NASDAQ
Market cap: $12.28B
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
Latest financial period: June 30, 2026
Filed with the SEC: July 30, 2026
Estimated earnings date: November 3, 2026
Profit #1459 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROIC | -43.1% | -48.0% | -42.8% | -61.8% |
Growth #54 of 1484 companies
Payout #1117 of 1484 companies
Safety #1165 of 1484 companies
Price #1379 of 1484 companies
